These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15637327)

  • 1. NINDS Reanalysis Committee's reanalysis of the NINDS trial.
    Mann J
    Stroke; 2005 Feb; 36(2):230-1; author reply 230-1. PubMed ID: 15637327
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "A graphic reanalysis of the NINDS Trial".
    Dewey HM; Churilov L; Blacker D; Bladin C; Davis SM; Donnan GA; Gates P; Gerraty RP; Hand P; Levi C; Lindley RI; Markus R; Read S
    Ann Emerg Med; 2010 Feb; 55(2):227-9; author reply 229. PubMed ID: 20116035
    [No Abstract]   [Full Text] [Related]  

  • 3. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Ingall TJ; O'Fallon WM; Asplund K; Goldfrank LR; Hertzberg VS; Louis TA; Christianson TJ
    Stroke; 2004 Oct; 35(10):2418-24. PubMed ID: 15345796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to: "A graphic reanalysis of the NINDS Trial".
    Saver JL; Gornbein J; Starkman S
    Ann Emerg Med; 2010 Feb; 55(2):226-7; author reply 229. PubMed ID: 20116034
    [No Abstract]   [Full Text] [Related]  

  • 5. A graphic reanalysis of the NINDS Trial.
    Hoffman JR; Schriger DL
    Ann Emerg Med; 2009 Sep; 54(3):329-36, 336.e1-35. PubMed ID: 19464756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroking the data: re-analysis of the NINDS trial.
    Magid D; Naviaux N; Wears RL
    Ann Emerg Med; 2005 Apr; 45(4):385-7. PubMed ID: 15795716
    [No Abstract]   [Full Text] [Related]  

  • 7. Emergency physician survey: recombinant tissue plasminogen activator for stroke.
    Mann J
    Ann Emerg Med; 2006 Oct; 48(4):476; author reply 477. PubMed ID: 16997689
    [No Abstract]   [Full Text] [Related]  

  • 8. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
    Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteplase and ischaemic stroke: have new reviews of old data helped?
    Lindley RI; Wardlaw JM; Sandercock PA
    Lancet Neurol; 2005 Apr; 4(4):249-53. PubMed ID: 15778104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Truths about the NINDS study: setting the record straight.
    Mann J
    West J Med; 2002 May; 176(3):192-4. PubMed ID: 12016245
    [No Abstract]   [Full Text] [Related]  

  • 11. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk adjustment effect on stroke clinical trials.
    Johnston KC; Connors AF; Wagner DP; Haley EC
    Stroke; 2004 Feb; 35(2):e43-5. PubMed ID: 14715975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis.
    Strbian D; Sairanen T; Meretoja A; Pitkäniemi J; Putaala J; Salonen O; Silvennoinen H; Kaste M; Tatlisumak T;
    Neurology; 2011 Jul; 77(4):341-8. PubMed ID: 21715707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Questions about authorisation of alteplase for ischaemic stroke.
    Shinton R
    Lancet; 2014 Aug; 384(9944):659-60. PubMed ID: 25152265
    [No Abstract]   [Full Text] [Related]  

  • 16. Alteplase for ischaemic stroke--much sooner is much better.
    Saver JL; Levine SR
    Lancet; 2010 May; 375(9727):1667-8. PubMed ID: 20472152
    [No Abstract]   [Full Text] [Related]  

  • 17. Be careful when extrapolating trial data to real life.
    Dudley N
    BMJ; 2003 Oct; 327(7418):812. PubMed ID: 14525900
    [No Abstract]   [Full Text] [Related]  

  • 18. When is enough enough?
    Donnan GA; Davis SM
    Stroke; 2001 Nov; 32(11):2710-1. PubMed ID: 11692042
    [No Abstract]   [Full Text] [Related]  

  • 19. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial.
    LaMonte MP; Bahouth MN; Magder LS; Alcorta RL; Bass RR; Browne BJ; Floccare DJ; Gaasch WR;
    Ann Emerg Med; 2009 Sep; 54(3):319-27. PubMed ID: 19101059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The stroke care revolution.
    Lancet Neurol; 2015 Apr; 14(4):341. PubMed ID: 25752414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.